| Primary |
| Pulmonary Tuberculosis |
37.6% |
| Tuberculosis |
31.2% |
| Disseminated Tuberculosis |
4.2% |
| Tuberculous Pleurisy |
3.5% |
| Lymph Node Tuberculosis |
2.7% |
| Drug Use For Unknown Indication |
2.1% |
| Endocarditis |
2.0% |
| Atypical Mycobacterial Infection |
1.9% |
| Infection |
1.8% |
| Immunosuppression |
1.7% |
| Product Used For Unknown Indication |
1.7% |
| Immunosuppressant Drug Therapy |
1.5% |
| Brucellosis |
1.3% |
| Meningitis Tuberculous |
1.2% |
| Staphylococcal Infection |
1.2% |
| Hypertension |
1.0% |
| Atrial Fibrillation |
0.9% |
| Prophylaxis |
0.9% |
| Endocarditis Staphylococcal |
0.8% |
| Constipation |
0.7% |
|
| Vomiting |
15.0% |
| Thrombocytopenia |
7.5% |
| Toxic Epidermal Necrolysis |
7.0% |
| Pyrexia |
6.6% |
| Drug Interaction |
6.1% |
| Weight Decreased |
5.6% |
| Jaundice |
5.2% |
| Rash |
5.2% |
| Acute Hepatic Failure |
4.2% |
| International Normalised Ratio Increased |
4.2% |
| Dyspnoea |
3.8% |
| Hyponatraemia |
3.8% |
| Interstitial Lung Disease |
3.3% |
| Optic Neuritis |
3.3% |
| Paradoxical Drug Reaction |
3.3% |
| Rash Erythematous |
3.3% |
| Renal Failure Acute |
3.3% |
| Respiratory Failure |
3.3% |
| Tubulointerstitial Nephritis |
3.3% |
| Drug Ineffective |
2.8% |
|
| Secondary |
| Tuberculosis |
20.0% |
| Pulmonary Tuberculosis |
19.9% |
| Product Used For Unknown Indication |
8.8% |
| Drug Use For Unknown Indication |
7.3% |
| Hiv Infection |
6.4% |
| Tuberculosis Of Eye |
5.0% |
| Rheumatoid Arthritis |
3.9% |
| Atypical Mycobacterial Infection |
3.5% |
| Staphylococcal Infection |
3.1% |
| Mycobacterium Avium Complex Infection |
3.0% |
| Meningitis Tuberculous |
2.5% |
| Hypertension |
2.4% |
| Lymph Node Tuberculosis |
2.3% |
| Endocarditis |
2.2% |
| Disseminated Tuberculosis |
2.2% |
| Prophylaxis |
1.9% |
| Tuberculous Pleurisy |
1.9% |
| Choroiditis |
1.3% |
| Pain |
1.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.1% |
|
| Vomiting |
16.2% |
| Pyrexia |
10.8% |
| Paradoxical Drug Reaction |
5.9% |
| Thrombocytopenia |
5.9% |
| Tuberculosis |
5.4% |
| Renal Failure Acute |
4.9% |
| Hypertension |
4.7% |
| Jaundice |
4.7% |
| Drug Interaction |
4.4% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.2% |
| Tuberculoma Of Central Nervous System |
4.2% |
| Weight Decreased |
4.2% |
| Rash Maculo-papular |
3.7% |
| Stevens-johnson Syndrome |
3.4% |
| Toxic Epidermal Necrolysis |
3.4% |
| Choroiditis |
2.9% |
| Rash |
2.9% |
| Sepsis |
2.9% |
| Hepatitis |
2.7% |
| Immune Reconstitution Syndrome |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
17.5% |
| Hiv Infection |
15.8% |
| Tuberculosis |
15.2% |
| Pulmonary Tuberculosis |
8.6% |
| Drug Use For Unknown Indication |
8.4% |
| Rheumatoid Arthritis |
4.6% |
| Atypical Mycobacterial Infection |
3.7% |
| Prophylaxis |
3.5% |
| Mycobacterium Avium Complex Infection |
3.4% |
| Infection |
3.2% |
| Staphylococcal Infection |
2.7% |
| Endocarditis |
2.4% |
| Pneumonia |
1.8% |
| Hypertension |
1.6% |
| Mycobacterial Infection |
1.6% |
| Ankylosing Spondylitis |
1.3% |
| Disseminated Tuberculosis |
1.2% |
| Meningitis Tuberculous |
1.2% |
| Pain |
1.2% |
| Endocarditis Staphylococcal |
1.2% |
|
| Vomiting |
14.8% |
| Pyrexia |
10.3% |
| Death |
7.8% |
| Tuberculosis |
7.8% |
| Weight Decreased |
5.3% |
| Serotonin Syndrome |
5.0% |
| Sepsis |
4.8% |
| Toxic Epidermal Necrolysis |
4.5% |
| Immune Reconstitution Syndrome |
4.3% |
| Vision Blurred |
4.3% |
| Hepatitis |
4.0% |
| White Blood Cell Count Decreased |
3.8% |
| Tachycardia |
3.5% |
| Renal Failure Acute |
3.3% |
| Interstitial Lung Disease |
3.0% |
| Pneumonia |
3.0% |
| Pulmonary Tuberculosis |
2.8% |
| Renal Failure |
2.8% |
| Respiratory Failure |
2.8% |
| Thrombocytopenia |
2.8% |
|
| Interacting |
| Tuberculosis |
20.3% |
| Pulmonary Tuberculosis |
12.2% |
| Immunosuppression |
8.5% |
| Mycobacterium Avium Complex Infection |
6.7% |
| Drug Use For Unknown Indication |
5.2% |
| Endocarditis Bacterial |
5.2% |
| Cancer Pain |
4.3% |
| Endocarditis |
4.3% |
| Staphylococcal Infection |
4.3% |
| Atypical Mycobacterial Infection |
4.1% |
| Hiv Infection |
3.7% |
| Breast Cancer Metastatic |
3.0% |
| Pyrexia |
3.0% |
| Stem Cell Transplant |
3.0% |
| Product Used For Unknown Indication |
2.4% |
| Subcutaneous Abscess |
2.2% |
| Wound Infection |
2.2% |
| Pain |
2.0% |
| Acute Myocardial Infarction |
1.8% |
| Depression |
1.8% |
|
| Drug Interaction |
23.6% |
| Hypertension |
12.3% |
| Drug Level Decreased |
8.5% |
| Vomiting |
6.6% |
| Alanine Aminotransferase Increased |
4.7% |
| Muscular Weakness |
4.7% |
| Thrombosis In Device |
4.7% |
| Tuberculosis |
4.7% |
| White Blood Cell Count Decreased |
3.8% |
| Hepatic Encephalopathy |
2.8% |
| Immunosuppressant Drug Level Decreased |
2.8% |
| Inadequate Analgesia |
2.8% |
| Liver Transplant Rejection |
2.8% |
| Pain |
2.8% |
| Pyrexia |
2.8% |
| Confusional State |
1.9% |
| Encephalopathy |
1.9% |
| Hepatic Failure |
1.9% |
| Hyperbilirubinaemia |
1.9% |
| Hypotension |
1.9% |
|
